Navigation Links
ScinoPharm to Invest in Tanvex Biologics
Date:8/31/2010

ScinoPharm to Invest in Tanvex Biologics -- TAINAN, Taiwan, Aug. 31 /PRNewswire-Asia/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Acquisitions, Mergers and Takeovers Click to view news release full screen  

ScinoPharm to Invest in Tanvex Biologics

 

TAINAN, Taiwan, Aug. 31 /PRNewswire-Asia/ -- ScinoPharm, a leading active pharmaceutical ingredient (API) developer and manufacturer headquartered in Taiwan, today announced an investment into Tanvex Biologics, Inc., a United States company registered in the State of Delaware. ScinoPharm's investment was in the form of tangible assets, intellectual properties, as well as cash.

Tanvex specializes in the development of biosimilars and biobetters, as well as the provision of contract research and contract manufacturing services for biologics. The company is currently establishing a cGMP facility in San Diego, California and will have research centers in both the U.S. and Taiwan. Tanvex is founded by Dr. Allen Chao, the founder and former Chairman and Chief Executive Officer of Watson Pharmaceuticals, Inc.

Dr. Hardy Chan, co-founder and Chief Scientific Officer of ScinoPharm, will become the Chief Executive Officer of Tanvex. Dr. Chao will remain as Executive Chairman of Tanvex.

About ScinoPharm Taiwan

ScinoPharm Taiwan, Ltd. is a leading process R&D and API manufacturing service provider to the global pharmaceutical industry. With research and manufacturing facilities in both Taiwan and mainland China, ScinoPharm offers a wide portfolio of services ranging from custom synthesis for early phase pharmaceutical activities to brand companies as well as APIs for the generic industry. For more information, please visit http://www.scinopharm.com .

About Tanvex Biologics

Tanvex Biologics, LLC is a US-based biopharmaceutical company specializing in the development of biopharmaceuticals.

Media Contact: ScinoPharm Taiwan, Ltd. Sabrian Wu Tel: +886-6-505-2869 Mobile Phone: +886-920-056-385 Email: sabrina.wu@scinopharm.com.tw
'/>"/>

SOURCE ScinoPharm Taiwan, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Signs Agreement to Divest Equity Interest in ScinoPharm
2. ScinoPharm Announces SafeBridge Potent Compound Safety Certification
3. Aethlon Medical to Present at Rodman & Renshaw Annual Global Investment Conference
4. Zimmer Holdings to Present at INVESTIndiana Equity Conference
5. Hill-Rom to Present at the INVESTIndiana Investor Conference
6. Curemark to Present at the Rodman & Renshaw Annual Global Investment Conference
7. JumpStart Ventures Invests In and Provides Entrepreneurial Assistance to Drug Development Company
8. Advanced Life Sciences Featured as Special Stock Pick by KonLin Investment Letter
9. Sangon & Bio Basic Inc. Closes $10 Million Round of Investment by Qiming Ventures
10. Water Street Healthcare Partners Announces New Investment in Medical Specialties Distributors, LLC
11. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Report Details What can be ... going to grow at the fastest rates? This visiongain ... trends, opportunities and prospects. Our 190-page report provides ... areas in the industry and the future market prospects. ... the all the major categories of the ophthalmic devices ...
(Date:1/19/2017)... Report Details ... Alzheimer,s Disease Therapeutics and ... our new study reveals trends, R&D progress, and predicted ... the Alzheimer,s disease therapeutics and diagnostics market. Our new ... - How is the Alzheimer,s disease therapeutics and diagnostics ...
(Date:1/19/2017)... Incretin Mimetics/GLP-1 Agonists, SNDRIs, Lipase Inhibitors, Serotonin Receptor Agonists, Sympathomimetic-GABA Receptor ... market is expected to grow at a CAGR of 27.1% ... 38.7% in the second half of the forecast period. The market ... to 2027. The market is estimated at $1,058 million in 2016, ... ...
Breaking Medicine Technology:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... ... wellness products to enhance people’s everyday lives, recently attended the January ECRM Trade ... , ATP Science is known for its large range of supplements that keep ...
(Date:1/20/2017)... ... January 20, 2017 , ... "TransFlare 4K Mystique comes with 44 ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Dragon Sensor,TransFlare 4K Mystique lens flare and light leak transitions have a very high-dynamic ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and earnest ... for each of his children. “The Angel” is the creation of published author, Marjorie ... York City, and impassioned writer. , When asked of her new book, Marjorie says, ...
(Date:1/20/2017)... ... January 20, 2017 , ... D R Burton Healthcare ... device, was featured in a study indicating superior performance against competitive products in ... of Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was published in ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Knowledge is God’s Lighthouse”: ... by faith. “Knowledge is God’s Lighthouse” is the creation of published author, Gene Gaapf, ... and poetry collections. , “I have been writing since high school and have ...
Breaking Medicine News(10 mins):